Amicus Therapeutics (NASDAQ:FOLD) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, ValuEngine reports.
Other equities analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 price objective on the stock in a report on Monday, November 4th. BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 21st. Cowen set a $31.00 target price on shares of Amicus Therapeutics and gave the stock a “buy” rating in a report on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a research note on Thursday, November 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Amicus Therapeutics in a report on Thursday, October 17th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $17.97.
Shares of Amicus Therapeutics stock opened at $10.02 on Wednesday. The stock’s fifty day simple moving average is $9.24 and its 200 day simple moving average is $10.45. The company has a current ratio of 6.20, a quick ratio of 6.10 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $2.74 billion, a PE ratio of -7.53 and a beta of 1.57. Amicus Therapeutics has a 12 month low of $7.11 and a 12 month high of $14.61.
Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.08. Amicus Therapeutics had a negative return on equity of 62.61% and a negative net margin of 216.02%. The firm had revenue of $48.80 million during the quarter, compared to analysts’ expectations of $48.05 million. During the same period in the previous year, the firm earned ($0.84) earnings per share. The company’s revenue was up 136.9% on a year-over-year basis. Analysts predict that Amicus Therapeutics will post -1.27 EPS for the current fiscal year.
In other news, CEO John F. Crowley sold 14,500 shares of the company’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $8.01, for a total transaction of $116,145.00. Following the completion of the transaction, the chief executive officer now directly owns 735,694 shares of the company’s stock, valued at $5,892,908.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John F. Crowley sold 20,000 shares of the company’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $9.02, for a total value of $180,400.00. Following the transaction, the chief executive officer now directly owns 755,694 shares of the company’s stock, valued at $6,816,359.88. The disclosure for this sale can be found here. Insiders sold a total of 134,500 shares of company stock worth $1,295,945 in the last three months. Company insiders own 2.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FOLD. Metropolitan Life Insurance Co NY grew its stake in shares of Amicus Therapeutics by 32.7% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 81,812 shares of the biopharmaceutical company’s stock worth $656,000 after acquiring an additional 20,179 shares in the last quarter. Millennium Management LLC lifted its position in shares of Amicus Therapeutics by 121.4% in the third quarter. Millennium Management LLC now owns 1,329,341 shares of the biopharmaceutical company’s stock worth $10,661,000 after purchasing an additional 728,940 shares in the last quarter. California State Teachers Retirement System boosted its holdings in Amicus Therapeutics by 11.8% during the third quarter. California State Teachers Retirement System now owns 398,710 shares of the biopharmaceutical company’s stock worth $3,198,000 after purchasing an additional 42,167 shares during the last quarter. Phoenix Holdings Ltd. acquired a new position in Amicus Therapeutics during the third quarter worth $8,960,000. Finally, Virtu Financial LLC acquired a new position in Amicus Therapeutics during the third quarter worth $240,000.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Recommended Story: New Google Finance Tool and Screening Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.